Cardiometabolic syndrome and associated factors among Ethiopian public servants, Addis Ababa, Ethiopia

Zeleke Geto1,2,*, Feyissa Challa2, Tadesse Lejisa2, Tigist Getahun2, Meron Sileshi2, Bikila Nagasa2, Yosef Tolcha2, Yeabkal Daniel2, Misrak Getnet3, Meseret Derbew Molla4, Maria Degef5, Abebe Bekele3 & Daniel Seifu5,6

Non-communicable diseases (NCDs) are increasingly becoming the global cause of premature death encompassing cardiovascular diseases (CVDs), cancer, respiratory diseases and diabetes mellitus. However, cardiometabolic risk factors in the general population, especially among the high-risk groups have rarely been assessed in Ethiopia. The study aimed to assess the prevalence of metabolic syndrome, its components and associated factors among staff in the Ethiopian Public Health Institute (EPHI). An institutional-based cross-section study was conducted from March to June 2018 among EPHI staff members. A total of 450 study participants were involved in the study, and the World Health Organization NCD STEPS survey instrument version 3.1 was used for the assessment. The biochemical parameters were analyzed by using COBAS 6000 analyzer. Statistical package for the social science (SPSS) version 20 was used for data analysis. Both bivariate and multivariate logistic regression analyses were used to identify associated risk factors. p value < 0.05 was considered for statistical significance. The overall prevalence of metabolic syndrome was 27.6% and 16.7% according to IDF and NCEP criteria respectively, with males having greater prevalence than females (35.8% vs 19.4%). Central obesity, low high-density lipoprotein (HDL) and hypertension had a prevalence of 80.2%, 41.3%, and 23.6%, respectively. In multivariate analysis increasing age and having a higher body mass index (25–29.9) were significantly associated with metabolic syndromes. The magnitude of metabolic syndrome was relatively high among public employees. Preventive intervention measures should be designed on the modification of lifestyle, nutrition and physical activities, and early screening for early identification of cardiometabolic risks factors should be practised to reduce the risk of developing cardiovascular diseases.

According to World Health Origination (WHO), non-communicable diseases (NCDs) are increasingly becoming the leading cause of morbidity and mortality involving every country worldwide1. NCDs, such as cardiovascular diseases (CVDs), different types of cancers, diabetes, and chronic respiratory diseases are the global leading causes of deaths which are responsible for 70% of all deaths worldwide2. From 36 million annual NCD deaths WHO report, CVDs stand the first place and accounts for 17.5 million followed by cancers (8.2 million), respiratory diseases (4.0 million) and diabetes mellitus (1.5 million)3.

NCDs shared common and key modifiable behavioural risk factors like unhealthy diet, lack of physical activity, use of alcohol, and tobacco; all that in turn leads to overweight/obesity, raised blood pressure, raised cholesterol, raised blood glucose and finally chronic diseases4. These risk factors for cardiometabolic syndrome have shown clustering and synergizing effects through time and then associated with a higher prevalence of NCDs, primarily CVDs and type 2 diabetes-related mortality4,7. The rise in the magnitude of cardiometabolic

1Department of Biomedical Science, College of Medicine and Health Sciences, Wollo University, Wollo, Dessie, Ethiopia. 2National Reference Laboratory for Clinical Chemistry, Ethiopian Public Health Institute, Addis Ababa, Ethiopia. 3Health System and Reproductive Health Research Directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia. 4Department of Biochemistry, College of Health Sciences, University of Gondor, Gondor, Ethiopia. 5Department of Biochemistry, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia. 6Division of Basic Sciences, Department of Biochemistry, University of Global Health Equity, Kigali, Rwanda. *email: zegetdm@gmail.com
risks factors, such as obesity, hyperglycemia, hypertension, and dyslipidemia; CVDs become the leading causes of premature mortality. Modifiable risk factors like high rates of smoking, alcohol consumption, poor diet and limited physical activities have been commonly practised and believed to be major risk factors of getting cardiometabolic diseases. While Ethiopia has significant progress in reducing the burden of infectious diseases, but there is little known about cardiometabolic diseases, their prevalence, and associated factors among government employees in Ethiopia. Therefore, our study aimed at evaluating the prevalence of cardiometabolic diseases and their associated factors among staff in EPHI.

Materials and methods

Study design and setting. An institutional-based cross-sectional study was conducted using the WHO STEPwise survey tool from March 2018 to June 2018 by experienced and well-trained data collectors. The survey involves three steps assessing the socio-demographic, behavioural characteristics, physical and clinical measurement, and biochemical measurement. The study includes all staff members of EPHI with excluding pregnant women during data collection.

Data collections. Demographic and lifestyle factors. Demographic, socioeconomic status, smoking status, alcohol consumption, physical activities status, fruit and vegetable consumption, history of raised blood pressure or medication for blood pressure was collected using standard personal digital assistants (PDAs) and transferred to the central server using an internet file streaming systems (IFSS).

Height and body mass were measured using calibrated scale and body mass index (BMI: kg/m²) were calculated. Waist circumference was measured in centimetres at the narrowest point between the lower costal border and the iliac crest using a tape meter and waist-to-height ratio (WHtR) calculated from waist circumference and height.

Blood pressure measurements were taken three times at the midpoint of the left arm after participants rest for at least five minutes or 30 min for those who took hot drinks using a Boso-Medicus Uno instrument (Boso, Germany) and average were taken. Physical activity was categorized into vigorous, moderate and sedentary (low) activity. A vigorous-intensity activity was defined as any activity that causes a large increase in breathing or heart rate if continued for at least 10 min and 3 days per week (e.g. running, carrying or lifting heavy loads, digging or construction work). Moderate-intensity activity was defined as any activity that causes a small increase in breathing or heart rate if continued for at least 10 min (brisk walking or carrying light loads). Moderate can also define by meeting any of the following criteria: three or more days of vigorous-intensity activity of at least 20 min per day; or five or more days of moderate-intensity activity or walking for at least 30 min per day. Physical activity related to work, transportation and leisure was assessed in terms of minutes that caused them to breathless or feel palpitation. Low-level physical activity involves a person not meeting any of the above-mentioned criteria for the moderate- or high-level categories.

Fruit and vegetable consumption was assessed by asking participants the number of days and serving they ate fruits and vegetables in a typical week. According to WHO guidelines, servings were measured by showing the study participants show cards showing that one standard serving size equals 80 g.

Alcohol consumption and smoking status were assessed based on a Yes/No response. Participants who consume any amount of alcohol in the past 30 days were considered alcohol consumers. Khat (Catha Edulis Forsk) is a green leaf that has a stimulant effect and is common in East Africa and the Middle East. The study participants were assesses based on the current chewer, previous chewer, and never chewer.

Biochemical analysis. Blood samples were collected from study participants after overnight fasting for 8–10 h. The collected specimen was allowed to clot for 30 min at room temperature and then centrifuged at 5000 rpm for 5 min. Serum separated from whole blood transferred into 2 aliquots of 3 ml using cryovials and stored at −80 °C at the EPHI National reference laboratory for Clinical Chemistry until the analysis is done.

Biochemical analysis (glucose, cholesterol, triglycerides, high-density lipoprotein (HDL-cholesterol and low-density lipoprotein (LDL-cholesterol) were analyzed using Cobas 6000® (Roche Diagnostics GmbH, Mannheim, Germany). Two levels of quality control (PreciControl Clini Chem Multi 1 and 2) were analyzed during the biochemical analysis series. In addition, the reference lab for Clinical Chemistry is an accredited laboratory by Ethiopia National Accreditation Office (ENAO). The laboratory analyses were done by well trained and experienced professionals with strictly followed laboratory standard operating procedures.

Criteria for metabolic syndrome classification. The definition criteria were based on the International Diabetes Federation (IDF) and the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) (Table 1). Central obesity can also be measured with WHR which is more convenient to use for all individuals with variable ethnic groups in different populations and both sexes having a single threshold value of 0.5.

Data processing and analysis. Descriptive data analyses were performed, along with bivariate and multivariate logistic regression for sex, age, smoking status, alcohol drinking status, physical activity level, khat chewing Status, fruit and vegetable consumption, BMI, WHR, raised blood pressure, lipid profile (normal vs abnormal) as a confounding factor. All factors with a p value < 0.2 in the bivariate analysis were further analyzed with multivariate logistic regression analysis. The data were analyzed using SPSS software version 20.00 (SPSS Inc. Chicago, IL, USA), and p values < 0.05 were considered statistically significant.
Ethical approval. Ethical clearance was obtained from Addis Ababa University Biochemistry Department ethics and research committee (DRERC). All study participants provided written informed consent. The identity of participants was not revealed, and an identification number was allocated. All methods used were also performed by the relevant guidelines and regulations.

**Results**

**General characteristics of the study participants.** A total of 450 (232 males, 218 females) study participants were included from all staff members of EPHI. In this study with 46% and 36% of males and females, the study participants were between 29 and 39 years, respectively. Half of the study participants were married and completed college/University completed and around 24% of the study participants during the study period had less than 1500 birr income per month (Table 2).

**Distribution of behavioural, clinical and biochemical characteristics.** About two-thirds of the study participants declared a moderate level of physical activity, but about 4% were smokers, 67% consumed alcohol, 4% chew Khat, and less than 1% consumed fruits and vegetables according to WHO criteria. In this study, 2% had hyperglycemia (≥ 126 mg/dl), 24% had high blood pressure, 19% had high serum triglycerides level (≥ 150 mg/dl), and 25% had a high LDL cholesterol level (≥ 130 mg/dl). Significant differences were

---

**Table 1. Classification criteria for metabolic syndrome based on IDF and NCEP ATP III.**

| Components | IDF criteria | NCEP ATP III criteria |
|------------|--------------|-----------------------|
| Abdominal obesity | Waist circumference ≥ 90 cm for men ≥ 80 cm for women | Waist circumference ≥ 102 cm for men ≥ 88 cm for women |
| Dyslipidaemia | Triglycerides ≥ 150 mg/dl Low HDL ≤ 40 mg/dl for men and ≤ 50 mg/dl for women | Triglycerides ≥ 150 mg/dl Low HDL ≤ 40 mg/dl for men and ≤ 50 mg/dl for women |
| Blood pressure | Systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg or current use of antihypertensive drugs | Systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg or current use of antihypertensive drugs |
| Fasting Blood Glucose | Fasting plasma glucose ≥ 100 mg/dl | Fasting plasma glucose ≥ 100 mg/dl |

| Characteristics | Total | Sex | Male n (%) | Female n (%) | p value |
|-----------------|-------|-----|------------|--------------|---------|
| Study participant, n (%) | 450   |     | 232 (51.6) | 218 (48.4)  |         |
| Mean age, y (SD) | 36.5 (10) | 38 (10) | 35 (10) | 0.018 |

**Table 2. Socio-demographic characteristics of the study participants stratified by sex, EPHI, Addis Ababa, Ethiopia, 2018 (n = 450).** Quartile 1 = < 1500 Birr, Quartile 2 = 1500–3173-birr, Quartile 3 = 3174–6676-birr Quartile 4 = > 6677 birr.
observed between male and female and smoking status, alcohol intake status, BMI, blood pressure, CO-based on IDF, and CO based on NCEP-ATPIII (p < 0.05) (Table 3).

Prevalence of determinant factors for metabolic syndrome. From the study participants, the prevalence of elevated blood pressure, raised fasting blood glucose, dyslipidemia, and central obesity were more prevalent among males and increases with increasing age. Among those consuming alcohol had high blood pressure (27.7% vs 15.3%) and were centrally obese by IDF (84.3% vs 72%) compared to those not consume alcohol. From study participants who had high BMI and had WHR above the cut-off value, elevated blood pressure was prevalent 18/21 (85.7%) and 92/320 (28.8%), respectively. The study also showed that Dyslipidemia was prevalent among overweight 102/167 (61.1%), obese 17/31 (54.8%) and those who had raised hsCRP 174/324 (53.4%). From those participants who had central obesity (80.2%) based on IDF criteria, all participants with 59–69 years age group had central obesity (Table 4).

Associated factors with raised blood pressure, raised blood glucose, dyslipidemia and central obesity. The results of the logistic regression analyses for raised blood pressure, raised blood glucose, dyslipidemia, and central obesity based on IDF are presented in Table 5. In logistic regression analysis, being female (ADJUSTED OR (AOR) = 0.07; 95% CI 0.02, 0.2], increasing age, overweight, were independent risk factors for central obesity based on IDF. Being a current smoker (AOR = 10.34; 95% CI 2.2, 48.7) and hypertensive (AOR = 4.8; 95% CI 1.24, 18.62) were also independent risk factors for raised fasting blood glucose based on WHO criteria. Overweight and raised WHR had a significant association with dyslipidemia in a multi logistic regression model with OR as follows overweight [AOR=1.68, (95% CI 1.07–2.63)] and raised WHR [AOR=1.74, (95% CI 1.07–2.81)].

Proportions of metabolic syndrome. In this study, 27.6% and 16.7% of the study participants had MetS based on IDF and NCEP ATP III, respectively. The prevalence of MetS based on both IDF and NCEP criteria was higher in males, 83/232 (35.8%) and 45/232 (19.4%), respectively compared to females. The prevalence of MetS increases with age increases and the age group between 59 and 69 years of age had the highest prevalence based on both criteria (Fig. 1).

Risk factors of metabolic syndrome. In multivariate analysis, sex, age, BMI, raised blood glucose; raised blood pressure and dyslipidemia were shown to be significant risk factors for metabolic syndrome based on IDF criteria (Table 5). The odd of developing metabolic syndrome is 32% smaller for females [AOR= 0.32, (95% CI 0.16–0.64)]. Age groups 39–48, 49–58, 59–69 and overweight were individual predictors for metabolic syndrome [AOR = 5.38, (1.72–16.8)], [AOR = 4.0, (1.09–14.7)], [AOR = 81.2 (9.4–669)] and [AOR = 4.67, (95% CI 2.27–17.6)], respectively. From our research result raised blood pressure and blood glucose and dyslipidemia were also significant risk factors for metabolic syndrome with AOR = 28 (95% CI 9.46–86.9), AOR = 126 (95% CI 6.7–2374) and AOR = 210 (95% CI 52–849), respectively. Almost similar results were observed using ATP III criteria on the significance of risk factors for metabolic syndrome. Central obesity was the constant component for IDF criteria while according to ATP III criteria it was a statistically significant risk factor for metabolic syndrome with [AOR = 9.56 (95% CI 4.11–22.3)]. Regarding sex difference, there was no statistical association for metabolic syndrome based on ATP III criteria (Table 6).

Summary of combined cardiometabolic risk factors. According to NCEP ATP III criteria, among the total study participants, only 109/450 (24.2%) had no risk factors for cardiometabolic diseases; out of which 65/232 (28%) were males. As shown in Fig. 2, more than three risk factors were more prevalent among male participants 10/232 (4.3%) as compared to female 3/218 (1.4%), having a crude percentage of 13/450 (2.9%). Nearly one-fourth of the study participants, 341/450 (75.8%) had at least one risk factor for metabolic syndrome and cardiometabolic risks. About 189/450 (42%) of the study participants had at least two or more risk factors for metabolic syndrome; of which the prevalence is higher among females 96/218 (44%) as compared to males 93/232 (40.1%). The prevalence of having at least three risk factors for metabolic syndrome was higher among males 45/232 (19.4%) from the total prevalence of 75/450 (16.7%) (Fig. 2).

Discussion

MetS is a constellation of different risk factors associated with a 5-fold increase in the incidence of Type 2 diabetes and a 2–3-fold increase in the incidence of CVDs48. Based on our findings the prevalence of overweight or obese, of were found higher than other studies conducted in Ethiopia national survey (1.2% obese and 5.2% overweight)49, northern Ethiopia, Mekele (4.1% obese and 26% overweight)50 and Northwest Ethiopia, Jimma obese (5.1%) and overweight (10.4%)51. Hypertension, the third most prevalent component (23.6%) for metabolic syndrome was higher than those reported in earlier studies 15.8% conducted in Ethiopia in 2015 national survey 29, 9.3% at Gibe Gibe field research center28 and 20% in male and 14% in female among working adults in Addis Ababa52. Possible explanations for the difference are stress conditions, lifestyle and genetic differences, and alcohol consumption status might have contributing factors. Our study participants had a high prevalence in alcohol consumption status as compared to other studies. The association of alcohol consumption with an increased incidence of hypertension was explained by different studies22,23. This showed that appropriate interventions were needed to reduce the burden of alcohol use, which could help to lower blood pressure levels44. The prevalence of hypertension was also higher when compared to a study done in Angola, 17.9%53 but lower in comparisons with studies done in
**Table 3.** Prevalence of behavioural clinical and biological characteristics of the study participant, EPHI, Addis Ababa, Ethiopia, 2018 (n = 450). *BMI* body mass index, raised blood pressure (SBP ≥ 140 and/or DBP ≥ 90 mmHg and/or on medication), hyperglycemia (fasting blood glucose ≥ 126 mg/dl and/or on medication), LDL low-density lipoprotein, HDL high-density lipoprotein, HDL low < 40/50 mg/dl (M/F) CO (central obesity waist circumference IDF ≥ 90/80 cm, NCEP-ATP III ≥ 102/88 cm male/female); WHtR (waist to height ratio), CO ≥ 0.5.

| Characteristics                                      | N (%) of total | Sex                  | Male n (%) | Female n (%) | p value |
|-------------------------------------------------------|----------------|----------------------|------------|--------------|---------|
| **Smoking status, n (%)**                             |                |                      |            |              |         |
| Never smoke                                          | 405 (90)       | 190 (81.9)           | 215 (98.6) |              | <0.005  |
| Current smoker                                       | 19 (4.2)       | 18 (7.8)             | 1 (0.5)    |              |         |
| Previous smoker                                      | 26 (5.8)       | 24 (10.3)            | 2 (0.9)    |              |         |
| **Alcohol intake status, n (%)**                      |                |                      |            |              | 0.001   |
| No                                                    | 150 (33.3)     | 60 (25.9)            | 90 (41.3)  |              |         |
| Yes                                                   | 300 (66.7)     | 172 (74.1)           | 128 (58.7) |              |         |
| **Physical activity level, n (%)**                    |                |                      |            |              | 0.365   |
| Vigorous                                              | 133 (29.6)     | 74 (31.9)            | 59 (27.1)  |              |         |
| Moderate                                              | 295 (66.5)     | 149 (64.2)           | 146 (67.0) |              |         |
| Low                                                   | 22 (4.8)       | 9 (3.9)              | 13 (4.9)   |              |         |
| **Khat chewing status, n (%)**                        |                |                      |            |              | <0.005  |
| Never chewed                                          | 379 (84.2)     | 166 (71.6)           | 213 (97.7) |              |         |
| Current chewer                                        | 19 (4.2)       | 19 (8.2)             | 0 (0)      |              |         |
| Previous chewer                                       | 52 (11.6)      | 47 (20.3)            | 5 (2.3)    |              |         |
| **Serving of fruit and vegetable per day (WHO)**      |                |                      |            |              |         |
| ≥5                                                    | 2 (0.4)        | 1 (0.4)              | 1 (0.5)    |              | 0.965   |
| <5                                                    | 448 (99.6)     | 231 (99.6)           | 217 (99.6) |              |         |
| **BMI (kg/m²)**                                       |                |                      |            |              |         |
| Normal                                                | 252 (56)       | 128 (55.2)           | 124 (56.9) |              | 0.001   |
| Overweight                                            | 167 (37.1)     | 97 (41.8)            | 70 (32.1)  |              |         |
| Obese                                                 | 31 (6.9)       | 7 (3.0)              | 24 (11.0)  |              |         |
| **Blood pressure, mmHg**                              |                |                      |            |              |         |
| Normal                                                | 344 (76.4)     | 172 (74.1)           | 172 (78.9) |              | 0.019   |
| Raised blood pressure                                 | 106 (23.6)     | 60 (25.9)            | 46 (21.1)  |              |         |
| **Lipid profiles**                                    |                |                      |            |              |         |
| Cholesterol < 200 mg/dl                               | 323 (71.8)     | 158 (68.1)           | 165 (75.7) |              | 0.074   |
| Cholesterol ≥ 200 mg/dl                               | 127 (28.2)     | 74 (31.9)            | 53 (24.3)  |              |         |
| Triglyceride < 150 mg/dl                              | 363 (80.7)     | 161 (64.4)           | 202 (92.7) |              | <0.005  |
| Triglyceride ≥ 150 mg/dl                              | 87 (19.3)      | 71 (30.6)            | 16 (7.3)   |              |         |
| Normal HDL mg/dl                                      | 264 (58.7)     | 141 (60.8)           | 123 (56.4) |              | 0.349   |
| Low HDL mg/dl                                         | 186 (41.3)     | 91 (39.2)            | 95 (43.6)  |              |         |
| Normal LDL (< 130) mg/dl                              | 337 (74.9)     | 166 (71.6)           | 171 (78.4) |              | 0.092   |
| High LDL (> 130) mg/dl                                | 113 (25.1)     | 66 (28.4)            | 47 (21.6)  |              |         |
| **Blood glucose**                                     |                |                      |            |              |         |
| Normal                                                | 439 (97.6)     | 224 (96.6)           | 215 (98.6) |              | 0.121   |
| Hyperglycemia                                         | 11 (2.4)       | 8 (3.4)              | 3 (1.4)    |              |         |
| **Dyslipidemia based on NCEP-ATPII**                  |                |                      |            |              |         |
| Normal                                                | 227 (50.4)     | 113 (48.7)           | 114 (52.3) |              | 0.447   |
| Dyslipidemia                                          | 223 (49.6)     | 119 (51.3)           | 104 (47.7) |              |         |
| **CO-based on IDF**                                   |                |                      |            |              | <0.005  |
| Normal                                                | 89 (19.8)      | 28 (12.1)            | 61 (28.0)  |              |         |
| Obese                                                 | 361 (80.2)     | 204 (87.9)           | 157 (72.0) |              |         |
| **CO-based on NCEP-ATPII**                            |                |                      |            |              | <0.005  |
| Normal                                                | 307 (68.2)     | 197 (84.9)           | 110 (50.5) |              |         |
| Obese                                                 | 143 (31.8)     | 35 (15.1)            | 108 (49.5) |              |         |
| **CO-based on WHtR**                                  |                |                      |            |              | <0.005  |
| Normal                                                | 130 (28.9)     | 68 (29.3)            | 62 (28.4)  |              | 0.839   |
| Obese                                                 | 320 (71.1)     | 164 (70.7)           | 156 (71.6) |              |         |
Table 4. Prevalence of blood pressure, blood glucose, lipid profiles abnormalities and central obesity of study participants at EPHI, Addis Ababa, Ethiopia, 2018 (n = 450). HTN hypertension, raised blood pressure (systolic BP ≥ 130 mmHg, diastolic BP ≥ 85 mmHg), DM diabetes mellitus (raised fasting glucose ≥ 100 mg/dl), Dyslipidemia (defined by raised triglyceride level ≥ 150 mg/dl and reduced HDL < 40 mg/dl in men and < 50 mg/dl in women). WHtR waist to height ratio (0.5 = normal and ≥ 0.5 obese), BMI body mass index.

| Characteristics                          | High blood pressure, n (%) | Elevated fasting blood glucose, n (%) | Dyslipidemia, n (%) | Centrally obese by IDF, n (%) |
|------------------------------------------|----------------------------|--------------------------------------|---------------------|-----------------------------|
| Sex                                      |                            |                                      |                     |                             |
| Male                                     | 60 (25.9)                  | 8 (3.4)                              | 119 (51.3)          | 204 (87.9)                  |
| Female                                   | 46 (21.1)                  | 3 (1.4)                              | 104 (47.7)          | 157 (72)                    |
| Total                                    | 106 (23.6)                 | 11 (2.4)                             | 223 (49.6)          | 361 (80.2)                  |
| Age                                      |                            |                                      |                     |                             |
| 18–28                                    | 9 (9.3)                    | 0 (0)                                | 46 (47.4)           | 49 (50.5)                   |
| 29–38                                    | 24 (12.9)                  | 1 (0.5)                              | 88 (47.3)           | 157 (84.4)                  |
| 39–48                                    | 39 (40.6)                  | 3 (3.1)                              | 58 (60.4)           | 89 (92.7)                   |
| 49–58                                    | 24 (43.6)                  | 5 (9.1)                              | 26 (47.3)           | 50 (91.9)                   |
| 59–69                                    | 10 (62.5)                  | 2 (12.5)                             | 5 (32.2)            | 16 (100)                    |
| Smoking status                           |                            |                                      |                     |                             |
| Never smoked                             | 91 (22.5)                  | 7 (1.7)                              | 202 (49.9)          | 319 (78.8)                  |
| Current smoker                           | 5 (26.3)                   | 3 (15.8)                             | 6 (31.6)            | 18 (94.7)                   |
| Previous smoker                          | 10 (38.5)                  | 1 (3.8)                              | 15 (57.7)           | 24 (92.3)                   |
| Alcohol consumption                      |                            |                                      |                     |                             |
| No                                       | 23 (15.3)                  | 1 (0.7)                              | 74 (49.3)           | 108 (72)                    |
| Yes                                      | 83 (27.7)                  | 10 (3.3)                             | 149 (49.7)          | 253 (84.3)                  |
| Physical activity level                  |                            |                                      |                     |                             |
| Vigorous                                 | 36 (27.1)                  | 2 (1.5)                              | 65 (48.9)           | 114 (83.7)                  |
| Moderate                                 | 63 (21.4)                  | 9 (3.1)                              | 146 (49.5)          | 233 (79)                    |
| Low                                      | 7 (31.8)                   | 0 (0)                                | 12 (54.5)           | 14 (63.6)                   |
| Khat chewing status of respondent        |                            |                                      |                     |                             |
| Never chewer                             | 90 (23.7)                  | 8 (2.1)                              | 183 (48.3)          | 300 (79.2)                  |
| Current chewer                           | 2 (10.5)                   | 1 (5.3)                              | 10 (52.6)           | 16 (84.2)                   |
| Previous chewer                          | 14 (26.9)                  | 2 (3.8)                              | 30 (57.7)           | 45 (86.5)                   |
| Days of fruit and vegetable intake per week |                        |                                      |                     |                             |
| ≥ 5                                      | 19 (19.4)                  | 1 (2.8)                              | 19 (52.8)           | 28 (77.8)                   |
| 3–5                                      | 19 (30.2)                  | 2 (3.2)                              | 31 (49.2)           | 46 (73)                     |
| < 3                                      | 80 (22.8)                  | 8 (2.3)                              | 173 (49.3)          | 287 (81.8)                  |
| BMI                                      |                            |                                      |                     |                             |
| Normal                                   | 46 (18.3)                  | 4 (1.6)                              | 104 (41.3)          | 173 (68.7)                  |
| Overweight                               | 42 (25.1)                  | 4 (2.4)                              | 102 (61.1)          | 158 (94.6)                  |
| Obese                                    | 18 (58.1)                  | 3 (9.7)                              | 17 (54.8)           | 30 (96.8)                   |
| WHtR                                     |                            |                                      |                     |                             |
| Normal                                   | 14 (10.8)                  | 1 (0.8)                              | 45 (34.6)           | 46 (35.4)                   |
| Obese                                    | 92 (28.8)                  | 10 (3.1)                             | 178 (55.6)          | 315 (98.4)                  |
| Raised blood pressure                    |                            |                                      |                     |                             |
| Normal                                   | NA                         | 4 (1.2)                              | 171 (49.7)          | 198 (73.9)                  |
| Hypertensive                             | NA                         | 7 (6.6)                              | 52 (49.1)           | 163 (89.6)                  |
| Raised blood glucose                     |                            |                                      |                     |                             |
| Normal                                   | 99 (22.6)                  | NA                                   | 219 (49.9)          | 321 (78.9)                  |
| Hyperglycemia                            | 7 (63.6)                   | NA                                   | 4 (36.4)            | 40 (93)                     |
| Lipid profile                            |                            |                                      |                     |                             |
| Normal                                   | 54 (23.8)                  | 7 (3.1)                              | NA                  | 171 (75.30)                 |
| Dyslipidemia                             | 52 (23.3)                  | 4 (1.8)                              | NA                  | 190 (85.2)                  |
| Central obesity by IDF                   |                            |                                      |                     |                             |
| Normal                                   | 19 (21.3)                  | 1 (1.1)                              | 33 (37.1)           | NA                          |
| Obese                                    | 163 (45.2)                 | 10 (2.8)                             | 190 (52.6)          | NA                          |
| Characteristics |Raised blood pressure|Raised blood glucose|Dyslipidemia|Central obesity based on IDF|
|---|---|---|---|---|
|COR (95% CI)|AOR (95% CI)|COR (95% CI)|AOR (95% CI)|COR (95% CI)|AOR (95% CI)|COR (95% CI)|AOR (95% CI)|COR (95% CI)|AOR (95% CI)|
|**Sex** | | | | | | | | | | |
|Male|1.00|–|1.00|--|1.00|–|1.00|–|1.00|–|
|Female|0.77 (0.5–1.20)|–|0.39 (0.10–1.49)|–|0.87 (0.6–1.25)|–|0.35 (0.22–0.58)|–|0.07 (0.02–0.2)*|
|**Age** | | | | | | | | | | |
|18–28|1.00|1.00|–|1.00|–|1.00|–|1.00|–|
|29–38|1.45 (0.65–3.25)|1.11 (0.48–2.58)|–|1.0 (0.61–1.63)|–|5.30 (3.02–9.30)|2.6 (1.05–6.55)| |
|39–48|6.69 (3.01–14.85)|4.27 (1.8–10.13)*|–|1.69 (0.96–3.0)|–|12.45 (5.24–29.62)|2.78 (0.68–11.5)| |
|49–58|7.57 (3.18–18.04)|4.53 (1.77–11.6)*|–|1.0 (0.51–1.93)|–|9.8 (3.6–26.7)|1.17 (0.25–5.46)| |
|59–69|16.3 (4.8–55.34)|8.62 (2.36–31.5)*|–|0.50 (0.16–1.56)|–|–|–| |
|**Smoking status** | | | | | | | | | | |
|Never smoked|1.00|–|1.00|--|1.00|–|1.00|–|1.00|–|
|Current smoker|1.23 (0.43–3.51)|–|10.66 (2.51–45)|10.34 (2.2–48.7)*|0.46 (0.17–1.24)|–|4.85 (0.64–36.9)|–| |
|Previous smoker|2.16 (0.95–4.92)|–|2.27 (0.27–19.2)|1.74 (0.2–15.42)|1.37 (0.62–3.06)|–|3.23 (0.75–13.96)|–| |
|**Alcohol drinking status** | | | | | | | | | | |
|No|1.00|1.00|1.00|–|1.00|–|1.00|–| |
|Yes|0.47 (0.28–0.79)|1.68 (0.96–2.93)|5.14 (0.65–40.5)|–|1.01 (0.68–1.5)|–|2.09 (1.30–3.36)|–| |
|**Physical activity level (WHO recommendation)** | | | | | | | | | | |
|Vigorous|1.00|–|1.00|--|1.00|–|1.00|–|1.00|–|
|Moderate|0.73 (0.46–1.17)|–|2.06 (0.44–9.67)|–|1.03 (0.68–1.54)|–|0.63 (0.36–1.1)|0.68 (0.35–1.31)| |
|Low|1.23 (0.47–3.33)|–|0.00 (0.00)|–|1.25 (0.51–3.11)|–|0.29 (0.11–0.79)|0.21 (0.06–0.77)| |
|**Khat chewing status of respondent** | | | | | | | | | | |
|Never chewer|1.00|–|1.00|--|1.00|–|1.00|–|1.00|–|
|Current chewer|0.38 (0.09–1.67)|–|2.58 (0.31–21.7)|–|1.19 (0.47–2.99)|–|1.4 (0.4–4.94)|–| |
|Previous chewer|1.18 (0.61–2.28)|–|1.85 (0.38–8.98)|–|1.46 (0.81–2.62)|–|1.69 (0.73–3.89)|–| |
|**Days of fruit and vegetable intake per week (WHO recommendation)** | | | | | | | | | | |
|≥ 5|1.00|–|1.00|--|1.00|–|1.00|–|1.00|–|
|3–5|1.8 (0.67–4.79)|–|1.15 (0.1–13.11)|–|0.87 (0.38–1.97)|–|0.77 (0.29–2.02)|–| |
|< 3|1.22 (0.52–2.9)|–|0.82 (0.1–6.72)|–|0.87 (0.44–1.73)|–|1.28 (0.56–2.94)|–| |
|**Body mass index (BMI)** | | | | | | | | | | |
|Normal|1.00|1.00|1.00|1.00|1.00|1.00|1.00|1.00|1.00|1.00|
|Overweight|1.51 (0.94–2.42)|0.86 (0.50–1.50)|1.52 (0.37–6.17)|1.31 (0.31–5.52)|2.23 (1.5–3.33)|1.68 (1.07–2.63)*|8.01 (3.89–16.5)|4.87 (2.23–10.6)*| |
|Obese|6.2 (2.84–13.55)|2.31 (0.95–5.59)|6.64 (1.41–31.2)|3.18 (0.57–17.8)|1.73 (0.82–3.66)|1.25 (0.57–2.74)|15.4 (1.84–102)|9.29 (1.07–80.71)*| |
|**WHtR** | | | | | | | | | | |
|Normal (< 0.5)|1.00|1.00|1.00|1.00|1.00|1.00|1.00|1.00|1.00|1.00|
|Obese (≥ 0.5)|3.34 (1.83–6.12)|1.66 (0.81–3.40)|4.16 (0.53–32.8)|–|2.37 (1.55–3.62)|1.74 (1.07–2.81)*|115 (44–298)|399 (82–1080)*| |
|**Raised blood pressure (≥ 140/90 mmHg)** | | | | | | | | | | |
|Normal|NA|NA|1.00|1.00|1.00|–|1.00|–|1.00|1.00|
|Hypertension|NA|NA|6.10 (1.72–20.9)|4.8 (1.24–18.62)*|0.97 (0.63–1.51)|–|4.43 (1.98–9.91)|1.94 (0.57–6.55)| |
|**Raised blood glucose level (≥ 126 mg/dl)** | | | | | | | | | | |
|Normal|1.00|1.00|NA|NA|1.00|–|1.00|–|1.00|–|
|Hyperglycemia|6.01 (1.72–20.95)|2.20 (0.56–8.61)|NA|NA|0.57 (0.17–1.99)|–|2.51 (0.32–19.85)|–| |
|**Lipid profile** | | | | | | | | | | |
|Normal|1.00|–|1.00|–|NA|NA|1.00|–|1.00|–|
|Dyslipidemia|0.97 (0.63–1.51)|–|0.57 (0.17–1.99)|–|NA|NA|1.89 (1.17–3.04)|–|1.04 (0.45–2.4)*|

Table 5. Bivariate and multivariate analyses of demographic and clinical risk factors for raised blood pressure, raised blood sugar, dyslipidemia and central obesity of study subjects. EPHI, Ethiopia, Addis Ababa, 2018 (n = 450). Raised blood pressure (systolic BP ≥ 130 mmHg, diastolic BP ≥ 85 mmHg), DM: diabetes mellitus (raised fasting glucose ≥ 100 mg/dl), central obesity (defined by a waist circumference ≥ 94 cm for men and ≥ 80 cm for women), Dyslipidemia (defined by raised triglyceride level ≥ 150 mg/dl and reduced HDL < 40 mg/dl in men and < 50 mg/dl in women). WHtR (waist to height ratio, COR (crude odds ratio), AOR (adjusted odds ratio). *Significant during multi logistic analysis.
The high prevalence of metabolic syndrome has been linked to urbanization, westernization, nutritional and epidemiological transition. Our result was also showed lower prevalence than the recent study conducted in Northern Ethiopia involving public employees in Mekele, which found a prevalence of metabolic syndrome was 16.7% using NCEP criteria while the IDF criteria yielded a higher prevalence of 27.6%. This higher prevalence of metabolic syndrome based on IDF criteria was due to a higher prevalence of central obesity which was one of the pre-request criteria for defining metabolic syndrome. Based on IDF criteria our result was fairly comparable to studies conducted in different regions and countries. The prevalence of metabolic syndrome in our study was less than from other studies. Differences in the age of study subjects, sample size, level of physical activity difference, and dietary intake. Concerning sex-difference, it is noted that males had a higher frequency associated cardiometabolic risk factors.

Findings from this study showed that the prevalence of metabolic syndrome among staff members of EPHI was 16.7% using NCEP ATP III criteria while the IDF criteria yielded a higher prevalence of 27.6%. This higher prevalence of metabolic syndrome based on IDF criteria was due to a higher prevalence of central obesity which is one of the pre-request criteria for defining metabolic syndrome. Based on IDF criteria our result was fairly comparable to studies conducted in different regions and countries. The prevalence of metabolic syndrome in our study was less than from other studies.

The high prevalence of metabolic syndrome has been linked to urbanization, westernization, nutritional and epidemiological transition. Our result was also showed lower prevalence than the recent study conducted in Northern Ethiopia involving public employees in Mekele, which found a prevalence of metabolic syndrome was 40% using IDF criteria. The explanation for this discordant may be due to the environmental and sampling methods in which we had used random sampling. However, the finding in this study was higher than other community-based studies using both NCEP ATP III and IDF criteria. Our result had found comparably higher prevalence than studies conducted among adults in the rural area of West China (10.8%) and health professionals in Brazil (4.5%).
Table 6. Bivariate and multivariate analyses of risk factor components for metabolic syndrome of study subjects. EPHI, Addis Ababa, Ethiopia, 2018 (n = 450). MS-IDF metabolic syndrome based on IDF (waist circumference ≥ 94/80 cm plus any two of the following (1) raised blood pressure ≥ 130/85, (2) raised fasting blood glucose ≥ 100 mg/dl, (3) fasting triglyceride ≥ 150 mg/dl and (4) HDL < 40/50 for male/female. MS-NCEP ATP III defined by any three of the following (1) waist circumference ≥ 102/88 male/female; (2) hypertriglyceridemia: serum TG ≥ 150 mg/dl, (3) low HDL-C < 40/50 mg/dl male/female, (4) hypertension: SBP ≥ 130 mmHg or DBP ≥ 85 mmHg and (5) fasting plasma glucose ≥ 110 mg/dl. *Significant during multi logistic analysis.

| Characteristics                          | MS-IDF | MS-NCEP ATP III |
|-----------------------------------------|--------|-----------------|
|                                          | COR (95% CI) | AOR (95% CI) | COR (95% CI) | AOR (95% CI) |
| **Sex**                                 |        |                 |              |              |
| Male                                    | 1.00   | 1.00            | 1.00         | -            |
| Female                                  | 0.42 (0.27–0.64) | 0.32 (0.16–0.64)* | 0.66 (0.4–1.09) | -            |
| **Age of respondents**                  |        |                 |              |              |
| 18–28                                   | 1.00   | 1.00            | 1.00         | 1.00         |
| 29–38                                   | 3.05 (1.36–6.81) | 2.1 (0.74–5.95) | 3.78 (1.09–13.0) | 1.24 (0.48–7.6) |
| 39–48                                   | 9.41 (4.12–21.5) | 5.38 (1.72–16.8)* | 13.6 (3.97–46.4) | 3.84 (0.79–18.8) |
| 49–58                                   | 7.42 (3.0–18.29) | 4.0 (1.09–14.7)* | 14 (3.88–50.4) | 3.3 (0.6–18.05) |
| 59–69                                   | 18.5 (5.34–64.3) | 81.2 (9.4–669)* | 18.8 (4.06–86.9) | 15 (1.74–129)* |
| **Smoking status**                      |        |                 |              |              |
| Never smoke                             | 1.00   | 1.00            | 1.00         | -            |
| Current smoker                          | 1.69 (0.65–4.4) | 1.46 (0.15–14) | 2.55 (0.94–6.97) | -            |
| Previous smoker                         | 2.89 (1.3–6.44) | 0.88 (0.23–3.38) | 2.04 (0.82–5.05) | -            |
| **Alcohol drinking status of respondent**|        |                 |              |              |
| No                                      | 1.00   | 1.00            | 1.00         | -            |
| Yes                                     | 1.72 (1.08–2.74) | 1.28 (0.62–2.63) | 1.72 (0.97–3.04) | -            |
| **Physical activity level (WHO recommendation)** |        |                 |              |              |
| Vigorous                                | 1.00   | -               | 1.00         | -            |
| Moderate                                | 0.93 (0.59–1.47) | 0.84 (0.49–1.44) | -            | -            |
| Low                                     | 0.94 (0.34–2.58) | -               | 1.34 (0.45–3.98) | -            |
| **Khat chewing status of respondent**   |        |                 |              |              |
| Never Chewed                            | 1.00   | -               | 1.00         | 1.00         |
| Current Chewer                          | 1.32 (0.49–3.58) | 1.51 (0.48–4.7) | 1.41 (0.21–9.3) | -            |
| Previous Chewer                         | 1.79 (0.98–3.28) | -               | 2.08 (1.06–4.08) | 1.66 (0.66–4.58) |
| **Serving of fruit and vegetable per day (WHO recommendation)** |        |                 |              |              |
| ≥ 5                                     | 1.00   | -               | -            | -            |
| < 5                                     | 0.38 (0.02–6.1) | -               | -            | -            |
| **Body mass index (BMI)**               |        |                 |              |              |
| Normal                                  | 1.00   | 1.00            | 1.00         | 1.00         |
| Overweight                              | 4.0 (2.77–7.0) | 4.67 (2.27–9.6)* | 9.04 (4.65–17.6) | 5.28 (2.12–13.7)* |
| Obese                                   | 5.45 (2.48–11.9) | 2.2 (0.6–8.05) | 11 (4.3–28.1) | 1.75 (0.49–6.21) |
| **Blood pressure**                      |        |                 |              |              |
| Normal                                  | 1.00   | 1.00            | 1.00         | 1.00         |
| Hypertensive                            | 6.05 (3.77–9.7) | 28 (9.46–86.9)* | 3.75 (2.22–6.32) | 4.55 (1.88–11.01)* |
| **Blood glucose**                       |        |                 |              |              |
| Normal                                  | 1.00   | 1.00            | 1.00         | 1.00         |
| Hyperglycemia                           | 28.5 (3.61–225) | 126 (6.7–2374)* | 9.55 (2.72–33.5) | 41.5 (4.75–362.9)* |
| **Dyslipidemia based on NCEP-ATPII**    |        |                 |              |              |
| Normal                                  | 1.00   | 1.00            | 1.00         | 1.00         |
| Dyslipidemia                            | 14.8 (8.12–27) | 210 (52–849)* | 13.9 (6.2–30.8) | 85.5 (21.9–332)* |
| **Waist circumference**                 |        |                 |              |              |
| Normal                                  | NA     | -               | 1.00         | 1.00         |
| Centrally obese                         | NA     | -               | 7.05 (4.09–12.16) | 9.56 (4.11–22.3)* |
The result also showed that the prevalence of metabolic syndrome, based on IDF criteria was 35.8% in males and 18.8% in females. This was in line with the study reported in Colombia who observe that the prevalence of metabolic syndrome in males was three times higher than in females. The possible explanation for the higher prevalence of metabolic syndrome in males is due to the majority of female participants are younger as compared to males. We have also found older age was significantly associated with metabolic syndrome. The other possible explanation for higher metabolic syndrome prevalence in males can be because of central obesity which was the primarily prevalent component in males (72%) than females (28%). However, in contradiction with our result, other studies have reported a higher prevalence of metabolic syndrome among females. The prevalence of metabolic syndrome was also found significantly higher in older age, which is in line with other studies. The reason is that ageing is characterized by a progressive deterioration in physiological functions and metabolic processes that generate reactive oxygen species as a by-product of biological oxidation. The oxidative damage of reactive oxygen species induces cellular dysfunction, which plays an important role in many pathological conditions like chronic low-level inflammation-induced metabolic syndrome. The predisposing factors to develop metabolic syndrome, includes being overweight [OR 4.67, (95% CI 2.27–9.6)], having raised blood pressure [OR 28, (95% CI 9.46–86.9)], raised fasting blood glucose [OR 126, (95% CI 6.7–2374)] and dyslipidemia [OR 210, (95% CI 52–849)]. These were also in line with other studies. Overweight characterized by unbalanced energy intake and expenditure could result in continued elevation of blood glucose level. Thus, it further results in hyper-secretion of insulin and leading to insulin resistance over time. Once insulin resistance occurs in different target organs for metabolic process dysregulation could be initiated such as lipid profile abnormalities, endothelial dysfunction, and inflammatory reactions.

This result revealed that smoking habits, alcohol consumption, physical activity status and serving of fruit and vegetables per day were not individual predictors for metabolic syndrome. These findings were consistent with other researcher’s reports. Another finding was in contrary found that smoking, alcohol use, fruit, and vegetable consumption were statistically significant factors for metabolic syndrome. The discordant between smoking and alcohol use with these research findings might be due to the amount and type of alcohol and smoking products taken by the study populations might be different. However, sex, age, BMI, raised blood pressure, raised blood glucose, dyslipidemia and raised hsCRP had statistical significance with metabolic syndrome in bivariate analysis. After adjusting confounders in logistic regression only age, BMI, elevated blood glucose, high blood pressure and dyslipidemia were independent predictors for metabolic syndrome. This was also in line with different studies. Three fourth of the participants had at least one component for metabolic syndrome. The prevalence of central obesity expressed as increased waist circumference was the first ranked abnormality, followed by low HDL and raised blood pressure which is acquiesced with many researchers. It is assumed that the luxurious lifestyle lies behind abdominal obesity and dyslipidemia for the most prevalent components of metabolic syndrome. High prevalence of abdominal/central obesity, low HDL and raised blood pressure emphasizes the susceptibility of the study population to CVD and Type 2 DM, especially in older age. Controlling body mass and fat with better physical activity and an appropriate diet are important to reduce the risk of CVDs. The prevalence also has been linked to urbanization, westernization, nutritional and epidemiological transition and this calls for urgent action by the policymakers and health managers to further emphasize the need for routine screening for all the components of Metabolic syndrome.

Figure 2. Summary of combined risk factors by sex of study participant based on ATP III definition, EPHI, Addis Ababa, Ethiopia, 2018 (n = 450).
Conclusion
From this study, it is possible to conclude the following: the prevalence of metabolic syndrome and its components were significantly high among the study population as compared to other studies like the country national survey. Central obesity, followed by dyslipidemia and hypertension were the most frequent components of metabolic syndrome. The prevalence of hypertension was found substantial as compared to the national survey report. Being male, over 39 years old, overweight, raised blood pressure elevated fasting blood glucose and dyslipidemia were significantly associated with metabolic syndrome. Twenty-four percent of the study participants were free from any risk factors for metabolic syndrome. About 16.7% of the study participants had ≥ 3 risk factors based on NCEP ATP III defining criteria.

Limitation of the study. The study employed a cross-sectional study design which could not conclude causality and effects. Moreover, this finding may not be generalized to a broader Ethiopian population since our study participants were an employee of a specific organization.

Data availability
The whole data supporting this study are included within the manuscript.

Received: 29 December 2020; Accepted: 1 October 2021
Published online: 19 October 2021

References
1. Ekpenyong, T., Udokang, C. E., Akpan, N. E. & Samson, E. E. Double burden, non-communicable diseases and risk factors evaluation in Sub-Saharan Africa: The Nigerian experience. Eur. J. Sustain. Dev. 2, 2 (2012).
2. World Health Organization. Non-Communicable Diseases Progress Monitor 2017 (World Health Organization, 2017).
3. World Health Organization. Global status Report on Noncommunicable Diseases (World Health Organization, 2014).
4. Alzeidan, R., Rabee, F., Mandil, A., Hersi, A. & Fayed, A. Non-communicable disease risk factors among employees and their families of a Saudi University: An epidemiological study. PLoS One https://doi.org/10.1371/journal.pone.0165036 (2016).
5. Kaukua, J., Turpeinen, A., Uusitupa, M. & Niskanen, L. Clustering of cardiovascular risk factors in type 2 diabetes mellitus: Prognostic significance and tracking. Diabetes Obes. Metab. https://doi.org/10.1111/j.1463-1326.2001.00093.x (2001).
6. Paper, R. The cardiometabolic syndrome and cardiovascular disease (2006).
7. Ala, A., Adelin, A. & Michèle, G. Cardiometabolic syndrome.
8. Carney, R., Cotter, J., Bradshaw, T., Firth, J. & Yung, A. R. Cardiometabolic risk factors in young people at ultra-high risk for psychosis: A systematic review and meta-analysis. Schizophr. Res. 170 (2–3), 290–300. https://doi.org/10.1016/j.schres.2016.01.010 (2016).
9. Krishnadas, R., Jashar, S., Telfer, S., Shivashankar, S. & McCreadie, R. G. Nicotine dependence and illness severity in schizophrenia. Brit. J. Psychiatry https://doi.org/10.1192/bjp.bp.111.107953 (2012).
10. National Institutes of Health. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults (U.S. Department of Health & Human, 2000).
11. Ashwell, M. & Gibson, S. Waist to height ratio is a simple and effective obesity screening tool for cardiovascular risk factors: Analysis of data from the British national diet and nutrition survey of adults aged 19–64 years. Obes. Facts https://doi.org/10.1159/000203663 (2009).
12. WHO. Enmo, 5–17 Years Old, pp. 2–3.
13. Bonita, R., Winkelman, R., Douglas, K. A. & de Courten, M. The WHO stepwise approach to surveillance (steps) of non-communicable disease risk factors. In Global Behavioural Risk Factor Surveillance, 2003.
14. Zimmet, P., Magliano, D., Matsuzawa, Y., Alberti, G. & Shaw, J. The metabolic syndrome: A global public health problem and a new definition. J. Atheroscler. Thromb. 12 (6), 295–300. https://doi.org/10.5551/jat.12.295 (2005).
15. Third Report of the National Cholesterol Education Program, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on, 01-3670, 2001. https://doi.org/10.1001/jama.285.19.2486.
16. Epidemiology, F. et al. Harmonizing the Metabolic Syndrome International Atherosclerosis Society; and International Association for the study of obesity. Circulation https://doi.org/10.1161/CIRCULATIONAHA.109.192644 (2009).
17. Ethiopia steps report on risk factors for non-communicable disease and prevalence of selected NCDs. Ethiopia steps report on risk factors for chronic non-communicable diseases and, no. December, 2016.
18. Gebremariam, L. W., Chi, C., Yatsuya, H. & Haregot, E. Non-communicable disease risk factor profile among public employees in a regional city in northern Ethiopia. Sci. Rep. https://doi.org/10.1038/s41598-018-27519-8 (2018).
19. Rajesh, P. N., Mossie, A. & Mezgebu, Y. Prevalence Of Metabolic Syndrome And Its Components In Jimma, vol. 3, no. 3, pp. 3685–1794, 2016. https://doi.org/10.18535/jimsuc/v3i3.7.
20. Tefera, T. B., Woldemichael, K., Tessema, F. & Alemseged, E. Prevalence of data from the british national diet and nutrition survey of adults aged 19–64 years. Obes. Facts https://doi.org/10.1159/000203663 (2009).
21. Tran, A. et al. Association between alcohol consumption and hypertension in Chinese adults: Findings from the CHNS. J. Atheroscler. Thromb. 12, 124–128. https://doi.org/10.5551/jat.12.295 (2005).
22. Tran, A. et al. Prevalence of metabolic syndrome among working adults in Ethiopia. Int. J. Hypertens. https://doi.org/10.4061/2011/193719 (2011).
23. Zhao, F. et al. Alcohol consumption and the risk of hypertension in men and women: A systematic review and meta-analysis. J. Clin. Hypertens. 14, 11. https://doi.org/10.1111/jch.12008 (2012).
24. Bhat, J. et al. Towards new recommendations to reduce the burden of alcohol-induced hypertension in the European Union. BMC Med. https://doi.org/10.1186/s11609-016-0773-4 (2017).
25. Manuel, V., Manuel, A. & Bèu, G. Prevalence of cardiovascular risk factors among workers at a private tertiary center in Angola, pp. 497–503, 2016.
26. Asreshegh, H., Tadesse, F. & Beyene, E. Prevalence and associated factors of hypertension among adults in Ethiopia: A community based cross-sectional study. BMC Res. Notes https://doi.org/10.1186/s13104-017-2966-1 (2017).
27. Daniel, O. J., Adejumoo, O. A., Adejumoo, E. N., Owohiba, R. S. & Braimah, R. W. Prevalence of hypertension among urban slum dwellers in Lagos, Nigeria. J. Urban Health https://doi.org/10.1007/s11524-013-9795-x (2013).
28. June, M. et al. Prevalence and awareness of Hypertension among urban and rural Adults in the Keta Municipality, Ghana, vol. 3, no. 3, pp. 155–163, 2017.
29. Worede, A., Alenu, S., Gelaw, Y. A. & Abebe, M. The prevalence of impaired fasting glucose and undiagnosed diabetes mellitus and associated risk factors among adults living in a rural Koladiba town, northwest Ethiopia. BMC Res. Notes https://doi.org/10.1186/1471-2288-10-371 (2017).
30. Shaw, J. E., Sicree, R. A. & Zimmet, P. Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87(1), 4–14. https://doi.org/10.1016/j.diabres.2009.10.007 (2010).
31. Oladapo, O. O. et al. A prevalence of cardiometabolic risk factors among a rural Yoruba south-western Nigerian population: A population-based survey. Cardiovasc. J. Afr. 21(1), 26–31 (2010).
32. Y. E. Gebreyes et al., Prevalence of high bloodpressure, hyperglycemia, dyslipidemia, metabolic syndrome and their determinants in Eritrea: The Evidence from the National NCDs STEPS, pp. 1–18, 2018.
33. Martínez-Torres, J. et al. A cross-sectional study of the prevalence of metabolic syndrome and associated factors in colombian collegiate students: ‘The fuprecol-collegues study. Int. J. Environ. Res. Public Health 14, 3. https://doi.org/10.3390/ijerph14030223 (2017).
34. Amin, T. T., Al Sultan, A. L., Mostafa, O. A., Darwish, A. A. & Al-Naboli, M. R. Profile of non-communicable disease risk factors among employees at a Saudi University. Asian Pac. J. Cancer Prev. 15(18), 7897–7907. https://doi.org/10.7314/APJCP.2014.15.18.7897 (2014).
35. Oberad, A. A., Ahmad, M. N., Haddad, F. H. & Azzeh, F. S. Alarming high prevalence of metabolic syndrome among Jordanian adults. Pak. J. Med. Sci. 36(6), 1377–1382. https://doi.org/10.12669/pjms.36.77714 (2015).
36. Farzadfar, F. et al. Discordance of metabolic syndrome and abdominal obesity prevalence according to different criteria in Andean highlanders: A community-based study. Diabetes Metab. Syndr. Clin. Res. Rev. 11, S359–S364. https://doi.org/10.1016/j.dsx.2017.03.016 (2017).
37. Kingue, S., Rakotoarimanana, S., Bompera, F. L. Prevalence of selected cardiometabolic risk factors among adults in urban & semi-urban hospitals in four sub-Saharan African countries. Cardiovasc. J. Afr. 26(3), 147–153. https://doi.org/10.1080/CVJA-2016-072 (2017).
38. Oguoma, V. M., Nwose, E. U. & Richards, R. S. Prevalence of inner metabolic syndrome and pre-diabetes among adolescents in southern Nigeria: A systematic review. Public Health 129(5), 413–423. https://doi.org/10.1016/j.puhe.2015.01.017 (2015).
39. Cameron, A. J., Magliano, D. J., Zimmet, P. Z., Welborn, T. & Shaw, J. E. The Metabolic Syndrome in Australia: Prevalence using four definitions. Diabetes Care 37(5), 471–478. https://doi.org/10.2337/dc10-1764 (2010).
40. Vidigal, F. D. C., Babio, N. & Salas-Salvadó, J. Prevalence of metabolic syndrome in Brazilian adults: A systematic review, 2013.
41. Kaduka, L. U. et al. Prevalence of metabolic syndrome among an urban population in Kenya. Diabetes Care 35(4), 887–893. https://doi.org/10.23736/S0149-1992.12-00080-6 (2012).
42. Gundogar, K. et al. Prevalence of metabolic syndrome according to ATP III and IDF criteria and related factors in Turkish adults. Arch. Med. Sci. 9(2), 243–253. https://doi.org/10.5114/ams.2013.34560 (2013).
43. Adeyemi, Y. A. et al. Prevalence of metabolic syndrome among apparently healthy adults in Ogun state, Nigeria. https://doi.org/10.1108/NFS-12-2016-0190 (2017).
44. Owoubi, E. O., Adeyemi, O. A. & Seekoei, E. Prevalence of metabolic syndrome in Nigeria: A systematic review. Public Health 129(5), 413–423. https://doi.org/10.1016/j.puhe.2015.01.017 (2015).
45. Kaduka, L. U. et al. Prevalence of metabolic syndrome among an urban population in Kenya. Diabetes Care 35(4), 887–893. https://doi.org/10.23736/S0149-1992.12-00080-6 (2012).
46. Da Carvalho Vidigal, F., Ribeiro, A. Q., Babio, N. & Salas-Salvadó, J. Prevalence of metabolic syndrome and pre-diabetes among adults attending healthcare facilities in Eastern Cape, South Africa: Open Public Health J. 10(1), 148–159. https://doi.org/10.2174/1874944501710010148 (2017).
47. Zhao, Y. et al. Prevalence and determinants of metabolic syndrome among adults in a rural area of northwest China. PLoS One 9, 3. https://doi.org/10.1371/journal.pone.0091578 (2014).
48. De Carvalho Vidigal, F., Ribeiro, A. Q., Babio, N., Salas-Salvadó, J. & Bressan, J. Prevalence of metabolic syndrome and pre-diabetes among adults attending healthcare facilities in Eastern Cape, South Africa: Open Public Health J. 10(1), 148–159. https://doi.org/10.2174/1874944501710010148 (2017).
49. Kaur, J. Assessment and screening of the risk factors in metabolic syndrome. Med. Sci. (Florence) 3(3), 140–152. https://doi.org/10.3390/medsci2030140 (2014).
50. Salminen, A., Ojala, J., Kaarniranta, K. & Kauppinen, A. Mitochondrial dysfunction and oxidative stress activate inflammasomes: Impact on the aging process and age-related diseases. Cell. Mol. Life Sci. https://doi.org/10.1007/s00018-012-0962-0 (2012).
51. Laakso, M. & Kussisuo, J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat. Rev. Endocrinol. 10(5), 293–302. https://doi.org/10.1038/nrendo.2014.29 (2014).
52. Wagner, A. et al. Sedentary behaviour, physical activity and dietary patterns are independently associated with the metabolic syndrome. Diabetes Metab. 38(5), 428–435. https://doi.org/10.1016/j.diabet.2012.04.005 (2012).
53. González-Muniesa, P. et al. Obesity. Nat. Rev. Dis. Prim. https://doi.org/10.1038/nrdp.2017.34 (2017).
54. Adamczak, M. & Wisecke, A. The adipose tissue as an endocrine organ. Semin. Nephrol. 33(1), 2–13. https://doi.org/10.1056/j. 377.10012-0003-s (2015).
55. Kaur, J. Assessment and screening of the risk factors in metabolic syndrome. Med. Sci. (Florence) 3(3), 140–152. https://doi.org/10.3390/medsci2030140 (2014).
56. Review, A. S. & Bank, S. D. Prevalence of metabolic syndrome in Mexico. Metab. Syndr. Relat. Disord. 11(11), 1–11. https://doi.org/10.1089/mrs.2017.0137 (2018).
57. Mabry, R. M., Reeves, M. M., Fakin, E. G., & Owen, N. Short report gender differences in prevalence of the metabolic syndrome in Gulf cooperation Council countries: A systematic review. Diab. Med. https://doi.org/10.1111/diabmed.1464-5491.2010.02998.x (2010).
58. Ntandou, G., Delisle, H., Agueh, V. & Fayomi, B. Abdominal obesity explains the positive rural-urban gradient in the prevalence of the metabolic syndrome in Benin, West Africa. Nutr. Res. 29(3), 180–189. https://doi.org/10.1016/j.nutres.2009.02.001 (2009).
Acknowledgements
We are very thankful to the St. Paul Millennium Medical College Hospital and staff members for their help
in collecting samples. We would also like to acknowledge the Ethiopian Public Health Institute staff for their
physical support.

Author contributions
Z.G., D.S., A.B. and M.D. designed and conceived the study. Z.G., A.B., F.C., M.G. and M.D.M. were responsible
for participant recruitment, data collection and data analysis. T.L., M.S., B.N., Y.T., T.G. and Y.D. analyzed test
parameters and interpreted results. Z.G. wrote the first draft of the manuscript and all authors reviewed and
edited the article and approved the final version of the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to Z.G.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021